U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    53,581.27
    -3,042.94 (-5.37%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Recap: Cardiovascular Systems Q1 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Cardiovascular Systems (NASDAQ:CSII) moved lower by 1.06% in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share rose 70.59% over the past year to ($0.05), which beat the estimate of ($0.22).

Revenue of $60,544,000 declined by 6.12% year over year, which beat the estimate of $56,290,000.

Looking Ahead

Cardiovascular Systems Sees Q2 Sales $63M-$67M Vs. $66.01M Est.

Conference Call Details

Date: Nov 04, 2020

Time: 04:30 PM

View more earnings on CSII

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.csi360.com%2F&eventid=2627049&sessionid=1&key=53389C8C3830083D12A1ABAC5CF38BE0&regTag=&sourcepage=register

Price Action

Company's 52-week high was at $55.22

Company's 52-week low was at $26.00

Price action over last quarter: Up 17.92%

Company Overview

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generates the vast majority of its revenue in the United States.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.